Omniab Share Price Today
(NASDAQ: OABI)

Name: Omniab Share Price Today (NASDAQ: OABI) - Omniab Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Omniab share price is $3.41 & ₹296.89 as on 6 Mar 2025, 2.30 'hrs' IST

$3.41

▲

0.06

(1.79%)

Market is closed - opens 8 PM, 06 Mar 2025

View live Omniab share price in Dollar and Rupees. Guide to invest in Omniab stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Omniab, along with analyst recommendations, forecasts, and comprehensive financials.

Omniab share price movements

Today's Low: $3.36
Today's High: $3.46
$3.41
1.47%
Downside
Day's Volatility :2.75%
Upside
1.3%
52 Weeks Low: $3.10
52 Weeks High: $6.02
$3.41
9.09%
Downside
52 Weeks Volatility :48.5%
Upside
43.36%

Omniab (OABI) Returns

Period	Omniab Inc	Index (Russel 2000)
3 Months	-11.89%	0.0%
6 Months	-17.03%	0.0%
1 Year	-42.4%	0.0%
3 Years	41.49%	-11.6%

Omniab (OABI) Key Statistics

in dollars & INR

Previous Close	$3.35
Open	$3.36
Today's High	$3.455
Today's Low	$3.36
Market Capitalization	$412.7M
Today's Volume	$329.6K
52 Week High	$6.02
52 Week Low	$3.1002
Revenue TTM	$20.4M
EBITDA	$-60.9M
Earnings Per Share (EPS)	$-0.62
Profit Margin	0.0%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-20.45%

How to invest in Omniab Stock (OABI) from India?

It is very easy for Indian residents to invest directly in Omniab from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Omniab stock in both Indian Rupees (INR) and US Dollars (USD). Search for Omniab or OABI on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Omniab or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Omniab shares which would translate to 0.255 fractional shares of Omniab as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Omniab, in just a few clicks!

Returns in Omniab (OABI) for Indian investors in Rupees

The Omniab stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Omniab investment value today

Current value as on today

₹62,666

Returns

₹37,334

(-37.33%)

Returns from Omniab Stock

₹42,399 (-42.4%)

Dollar Returns

₹5,065 (+5.06%)

Indian investors sentiment towards Omniab (OABI)

-67%

Period: Feb 3, 2025 to Mar 5, 2025. Change in 30 Days versus previous period

Search interest for Omniab Stock from India on INDmoney has decreased by -67% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Omniab

Avista Capital Holdings LP
13.07%
HHG PLC
6.58%
BlackRock Inc
5.93%
Vanguard Group Inc
4.18%
Macquarie Group Ltd
3.55%
Dimensional Fund Advisors, Inc.
2.50%

Analyst Recommendation on Omniab

Buy

92%Buy

7%Hold

0%Sell

Based on 14 Wall street analysts offering stock ratings for Omniab(by analysts ranked 0 to 5 stars)

Based on 14 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Omniab Stock (OABI)

What analysts predicted

Upside of 182.26%

Target:

$9.63

Current:

$3.41

Insights on Omniab Stock (Ticker Symbol: OABI)

Price Movement
In the last 1 year, OABI stock has moved down by -42.4%
Decreasing Revenue
Revenue is down for the last 2 quarters, 7.61M → 4.17M (in $), with an average decrease of 45.2% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, -13.63M → -16.37M (in $), with an average decrease of 20.1% per quarter
OABI vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 66.5% return, outperforming this stock by 108.9%
Price to Sales
ForOABI every $1 of sales, investors are willing to pay $16.9, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $14.2 for every $1 of sales.

OABI Omniab Financials in INR & Dollars

	FY19	Y/Y Change
Revenue	$18.3M	-
Net Income	$-13.6M	-
Net Profit Margin	-74.18%	-

	FY20	Y/Y Change
Revenue	$23.3M	↑ 27.02%
Net Income	$-17.6M	↑ 29.2%
Net Profit Margin	-75.46%	↓ 1.28%

	FY21	Y/Y Change
Revenue	$34.7M	↑ 49.34%
Net Income	$-27.0M	↑ 54.02%
Net Profit Margin	-77.82%	↓ 2.36%

	FY22	Y/Y Change
Revenue	$59.1M	↑ 70.02%
Net Income	$-22.3M	↓ 17.41%
Net Profit Margin	-37.8%	↑ 40.02%

	FY23	Y/Y Change
Revenue	$34.2M	↓ 42.17%
Net Income	$-50.6M	↑ 126.65%
Net Profit Margin	-148.16%	↓ 110.36%

	Q2 FY23	Q/Q Change
Revenue	$6.9M	↓ 58.95%
Net Income	$-14.7M	↑ 141.44%
Net Profit Margin	-212.04%	↓ 175.99%

	Q3 FY23	Q/Q Change
Revenue	$5.5M	↓ 21.15%
Net Income	$-15.7M	↑ 6.86%
Net Profit Margin	-287.35%	↓ 75.31%

	Q4 FY23	Q/Q Change
Revenue	$4.8M	↓ 11.96%
Net Income	$-14.1M	↓ 10.71%
Net Profit Margin	-291.44%	↓ 4.09%

	Q1 FY24	Q/Q Change
Revenue	$3.8M	↓ 21.17%
Net Income	$-19.0M	↑ 34.92%
Net Profit Margin	-498.84%	↓ 207.4%

	Q2 FY24	Q/Q Change
Revenue	$7.6M	↑ 100.32%
Net Income	$-13.6M	↓ 28.11%
Net Profit Margin	-179.03%	↑ 319.81%

	Q3 FY24	Q/Q Change
Revenue	$4.2M	↓ 45.21%
Net Income	$-16.4M	↑ 20.12%
Net Profit Margin	-392.45%	↓ 213.42%

	FY19	Y/Y Change
Profit	$18.3M	-

	FY20	Y/Y Change
Profit	$23.3M	↑ 27.02%

	FY21	Y/Y Change
Profit	$19.8M	↓ 14.99%

	FY22	Y/Y Change
Profit	$42.8M	↑ 116.52%

	FY23	Y/Y Change
Profit	$34.2M	↓ 20.23%

	Q2 FY23	Q/Q Change
Profit	$2.1M	↓ 83.38%

	Q3 FY23	Q/Q Change
Profit	$633.0K	↓ 69.65%

	Q4 FY23	Q/Q Change
Profit	$-112.0K	↓ 117.69%

	Q1 FY24	Q/Q Change
Profit	$-1.1M	↑ 925.0%

	Q2 FY24	Q/Q Change
Profit	$1.5M	↓ 231.79%

	Q3 FY24	Q/Q Change
Profit	$4.2M	↑ 175.74%

	FY19	Y/Y Change
Operating Cash Flow	$-5.2M	-
Investing Cash Flow	$-12.1M	-
Financing Cash Flow	$17.3M	-

	FY20	Y/Y Change
Operating Cash Flow	$3.6M	↓ 169.66%
Investing Cash Flow	$-27.0M	↑ 123.07%
Financing Cash Flow	$23.4M	↑ 35.11%

	FY21	Y/Y Change
Operating Cash Flow	$-5.7M	↓ 256.73%
Investing Cash Flow	$-4.0M	↓ 85.08%
Financing Cash Flow	$9.7M	↓ 58.49%

	FY22	Y/Y Change
Operating Cash Flow	$-3.6M	↓ 36.76%
Investing Cash Flow	$-73.3M	↑ 1721.44%
Financing Cash Flow	$110.7M	↑ 1041.99%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-10.0M	↓ 136.2%
Investing Cash Flow	$7.8M	↓ 120.93%
Financing Cash Flow	$478.0K	↓ 145.74%

Omniab Technicals Summary

Sell

Neutral

Buy

Omniab is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Omniab (OABI) Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Omniab Inc	3.02%	-17.03%	-42.4%	41.49%	41.49%
Regeneron Pharmaceuticals, Inc.	-1.42%	-40.28%	-29.31%	11.08%	44.83%
Beone Medicines Ltd	17.63%	36.87%	64.37%	45.89%	71.3%
Vertex Pharmaceuticals Incorporated	1.94%	4.92%	19.37%	108.73%	123.83%
Alnylam Pharmaceuticals, Inc.	-8.03%	-0.89%	66.53%	52.9%	126.66%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Omniab Inc	NA	NA	NA	-0.58	-0.2	-0.14	NA	2.43
Regeneron Pharmaceuticals, Inc.	17.86	17.86	1.01	43.09	0.16	0.07	0.01	273.57
Beone Medicines Ltd	NA	NA	NA	1.43	-0.19	-0.06	NA	31.22
Vertex Pharmaceuticals Incorporated	32.84	NA	1.34	18.07	-0.03	0.13	NA	63.87
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	0.57	-15.01	-0.03	NA	0.52

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Omniab Inc	Buy	$412.7M	41.49%	NA	0.0%
Regeneron Pharmaceuticals, Inc.	Buy	$73.8B	44.83%	17.86	31.07%
Beone Medicines Ltd	NA	$29.1B	71.3%	NA	-16.92%
Vertex Pharmaceuticals Incorporated	Buy	$124.9B	123.83%	32.84	-4.86%
Alnylam Pharmaceuticals, Inc.	Buy	$31.4B	126.66%	NA	-12.37%

About Omniab

OmniAb, Inc., a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic, a bispecific rat, and OmniClic, a bispecific chicken, designed for discovery of bispecific antibody applications; OmniTaur, which provides unique structural characteristics of cow antibodies for complex targets; and OmniDeep, a suite of in silico, an AI and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.

Organization	Omniab
Employees	106
CEO	Mr. Matthew W. Foehr
Industry	Healthcare

Management People of Omniab

Name	Title
Mr. Matthew W. Foehr	President, CEO & Director
Mr. Kurt A. Gustafson	Executive VP of Finance & CFO
Mr. Charles S. Berkman J.D.	Chief Legal Officer & Secretary
Ms. Cia McCaffrey	Vice President of People & Talent
Dr. Bill Harriman Ph.D.	Senior Vice President of Antibody Discovery
Ms. Marie-Cecile van de Lavoir D.V.M., Ph.D.	Senior Vice President of Technical Operations & Genetics
Dr. Christel Iffland Ph.D.	Senior Vice President of Antibody Technologies
Dr. Yasmina Noubia Abdiche Ph.D.	Senior Vice President of Exploratory Research
Ms. Donna Ventura CPA	Senior VP & Corporate Controller

Important FAQs about investing in OABI Stock from India :

What is Omniab share price today?

Omniab share price today stands at $3.41, Open: $3.36 ; Previous Close: $3.35 ; High: $3.46 ; Low: $3.36 ; 52 Week High: $6.02 ; 52 Week Low: $3.10.

The stock opens at $3.36, after a previous close of $3.35. The stock reached a daily high of $3.46 and a low of $3.36, with a 52-week high of $6.02 and a 52-week low of $3.10.

Can Indians buy Omniab shares?

Yes, Indians can invest in the Omniab (OABI) from India.

With INDmoney, you can buy Omniab at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Omniab at zero transaction cost.

How can I buy Omniab shares from India?

It is very easy to buy Omniab from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Omniab (OABI) be purchased?

Yes, you can buy fractional shares of Omniab with INDmoney app.

What are the documents required to start investing in Omniab stocks?

To start investing in Omniab, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.